GH Research PLC
GHRS12.785USD
+0.035+0.27%
收盤 12/24, 13:00（美東）報價延遲15分鐘
793.05M總市值
虧損本益比TTM
關於 GH Research PLC 公司
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
GH Research PLC簡介
公司代碼GHRS
公司名稱GH Research PLC
上市日期Jun 25, 2021
CEOValcheva (Velichka)
員工數量50
證券類型Ordinary Share
年結日Jun 25
公司地址Joshua Dawson House
城市DUBLIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Ireland
郵編D02 RY95
電話35314378334
網址
公司代碼GHRS
上市日期Jun 25, 2021
CEOValcheva (Velichka)
GH Research PLC公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Velichka (Villy) Valcheva, M.D.
Dr. Velichka (Villy) Valcheva, M.D.
Chief Executive Officer
Chief Executive Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Florian Schonharting
Mr. Florian Schonharting
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
14.82M
--
Mr. Michael Forer
Mr. Michael Forer
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Ms. Julie Ryan
Ms. Julie Ryan
Vice President - Finance
Vice President - Finance
--
--
Mr. Magnus Halle
Mr. Magnus Halle
Managing Director, Ireland
Managing Director, Ireland
--
--
Mr. Dermot Hanley
Mr. Dermot Hanley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Duncan Moore, Ph.D.
Dr. Duncan Moore, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
Lynx1 Capital Advisors LLC
13.87%
RA Capital Management, LP
12.38%
RTW Investments L.P.
8.98%
其他
26.65%
持股股東
持股股東
佔比
Schonharting (Florian)
23.90%
BVF Partners L.P.
14.23%
Lynx1 Capital Advisors LLC
13.87%
RA Capital Management, LP
12.38%
RTW Investments L.P.
8.98%
其他
26.65%
股東類型
持股股東
佔比
Individual Investor
26.78%
Investment Advisor
24.87%
Hedge Fund
22.50%
Venture Capital
13.30%
Investment Advisor/Hedge Fund
9.89%
Research Firm
1.24%
Bank and Trust
0.04%
其他
1.38%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
79
43.69M
70.44%
-1.29M
2025Q2
81
63.73M
102.74%
+7.16M
2025Q1
80
63.74M
102.77%
+7.17M
2024Q4
74
51.85M
85.10%
-3.62M
2024Q3
76
51.78M
99.44%
-4.46M
2024Q2
78
51.68M
99.26%
-4.52M
2024Q1
77
50.90M
97.75%
-4.57M
2023Q4
73
50.91M
97.80%
-2.89M
2023Q3
74
50.54M
97.15%
-4.64M
2023Q2
82
51.15M
98.33%
-4.53M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Schonharting (Florian)
14.82M
23.9%
--
--
Dec 31, 2024
BVF Partners L.P.
8.83M
14.23%
--
--
Jun 30, 2025
Lynx1 Capital Advisors LLC
6.75M
10.88%
+303.01K
+4.70%
Jun 30, 2025
RA Capital Management, LP
7.68M
12.38%
+732.05K
+10.54%
Jun 30, 2025
RTW Investments L.P.
5.54M
8.93%
+40.69K
+0.74%
Jun 30, 2025
Fidelity Management & Research Company LLC
5.09M
8.21%
+842.57K
+19.83%
Jun 30, 2025
Cormorant Asset Management, LP
2.01M
3.24%
--
--
Jun 30, 2025
Terwey (Theis)
4.69M
7.57%
-1.50M
-24.16%
Jun 30, 2025
Deep Track Capital LP
2.00M
3.22%
--
--
Jun 30, 2025
Millennium Management LLC
203.65K
0.33%
+203.65K
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
AdvisorShares Psychedelics ETF
5.66%
iShares MSCI Ireland ETF
0.87%
Virtus LifeSci Biotech Clinical Trials ETF
0.76%
SPDR S&P International Small Cap ETF
0.02%
ALPS Medical Breakthroughs ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
AdvisorShares Psychedelics ETF
佔比5.66%
iShares MSCI Ireland ETF
佔比0.87%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.76%
SPDR S&P International Small Cap ETF
佔比0.02%
ALPS Medical Breakthroughs ETF
佔比0%
Fidelity Nasdaq Composite Index ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
GH Research PLC的前五大股東是誰？
GH Research PLC的前五大股東如下：
Schonharting (Florian)持有股份：14.82M佔總股份比例：23.90%。
BVF Partners L.P.持有股份：8.83M佔總股份比例：14.23%。
Lynx1 Capital Advisors LLC持有股份：6.75M佔總股份比例：10.88%。
RA Capital Management, LP持有股份：7.68M佔總股份比例：12.38%。
RTW Investments L.P.持有股份：5.54M佔總股份比例：8.93%。
Schonharting (Florian)持有股份：14.82M佔總股份比例：23.90%。
BVF Partners L.P.持有股份：8.83M佔總股份比例：14.23%。
Lynx1 Capital Advisors LLC持有股份：6.75M佔總股份比例：10.88%。
RA Capital Management, LP持有股份：7.68M佔總股份比例：12.38%。
RTW Investments L.P.持有股份：5.54M佔總股份比例：8.93%。
GH Research PLC的前三大股東類型是什麼？
GH Research PLC 的前三大股東類型分別是：
Schonharting (Florian)
BVF Partners L.P.
Lynx1 Capital Advisors LLC
Schonharting (Florian)
BVF Partners L.P.
Lynx1 Capital Advisors LLC
有多少機構持有GH Research PLC(GHRS)的股份？
截至2025Q3，共有79家機構持有GH Research PLC的股份，合計持有的股份價值約為43.69M，占公司總股份的70.44% 。與2025Q2相比，機構持股有所增加，增幅為-32.30%。
哪個業務部門對GH Research PLC的收入貢獻最大？
在--，--業務部門對GH Research PLC的收入貢獻最大，創收--，占總收入的--% 。
